Loading…
← CockpitCompetitor Analysis › 603014.SS Shandong Weigao Blood Purification Products Co., Ltd. Class AOpen in the cockpit ↗

Shandong Weigao Blood Purification Products Co., Ltd. Class A603014.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties

Weigao Group subsidiary making dialysis and blood-purification consumables like dialyzers and blood tubing.

≈ A Chinese Fresenius Medical Care/Baxter dialysis-consumables makerMomentum leader 94
Mkt cap
$3.63B
US dollars, full cap
Free float
55%
of shares outstanding
$/day
$13.0M
20-day average traded
Fwd P/E
20.4×
forward earnings
ROIC−WACC
n/a
WACC 5.0%
Hurdle
-9 pp
Req g minus delivered
Next earnings
131 days
29 Mar 2027
Close · CNYCN¥34.63
1D-1.0%
1W+1.8%
1M+17.4%
3M+1.6%
6M-0.8%
YTD-12.6%
1Y-25.6%
ATR %2.8%
52w lowhigh29.3% off high

What Shandong Weigao Blood Purification Products does

Weigao Group subsidiary making dialysis and blood-purification consumables like dialyzers and blood tubing.

Sells single-use items that each dialysis session consumes, so demand repeats for as long as patients are treated, usually several times a week. Hospital purchasing tenders set how much it sells and at what price, and the Weigao group's network helps it reach hospitals.

In one line: A Chinese Fresenius Medical Care/Baxter dialysis-consumables maker.

Products and services

  • Dialyzers
  • Blood tubing sets
  • Peritoneal dialysis consumables

Customers

  • Dialysis centers/hospitals

Where it sits in the supply chain

  • Health Care
  • Medical devices
  • Dialysis & blood-purification…

What could go right

  • China dialysis patient-volume growth

What could go wrong

  • Volume-based procurement price cuts

Moat: narrow (installed base, regulatory licence). Weigao's hospital distribution scale and device registrations support incumbency.

Headquarters: Weihai, Shandong, China · Employees: 3,734

Named competitors

Shandong Weigao Blood Purification Products at a glance

Size Shandong Weigao Blood Purification Products (603014.SS) is a China Health Care company (Medical Specialties) with a market value of $3.63B, the 666th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥34.63 on 18 Nov 2026.

Performance Over six months the shares fell 0.8%, against +3.2% for the median peer and -20.0% for the China market (cap-weighted) — 10th lowest of 21 in its peer set.

Growth Revenue grew 4.0% over the last twelve months (peer median +7.4%).

Valuation It trades at 20.4× forward earnings against a peer median of 24.4× (7th cheapest of 19).

Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -9 pp: the price already allows for a slowdown.

Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026Peer median 105603014.SS 100
Six months, rebased to 100: Shandong Weigao Blood Purification Products against the median of its 20 peers (local-currency closes).

Shandong Weigao Blood Purification Products financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥4.31BCN¥3.75BCN¥3.60BCN¥3.53BCN¥3.43B
Revenue growth—+4%+2%+3%—
Gross profitn/aCN¥1.41BCN¥1.43BCN¥1.44BCN¥1.37B
EBITDAn/aCN¥778MCN¥703MCN¥601MCN¥562M
Net incomeCN¥665MCN¥482MCN¥449MCN¥442MCN¥315M
Free cash flowCN¥1.09BCN¥665MCN¥449MCN¥56.2MCN¥467M
Capital expenditureCN¥200MCN¥160MCN¥179MCN¥233MCN¥280M
Total debtCN¥181MCN¥2.93MCN¥67.6MCN¥34.7MCN¥134M

Quarterly statements and history in the cockpit →

Shandong Weigao Blood Purification Products competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%+75%-20%0%+20%TECN1SXP4203AMBU-BNVST002432AXGNPLSECDNAFIE603658TMDX688301603301300003IRTCAFX002223STVN688114603014.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Shandong Weigao Blood Purification Products is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%25×50×75×100×TECN1SXP4203AMBU-BNVST002432AXGNCDNAFIE603658TMDX688301603301IRTC603014.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shandong Weigao Blood Purification Products is the large dot.

Capital: growth delivered against growth the price implies

0%+25%+50%+75%0%50%TECN1SXP4203NVST002432AXGNFIETMDX603301300003IRTC688114603014.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shandong Weigao Blood Purification Products is the large dot.

Shandong Weigao Blood Purification Products competitors and peer comparison

Head to head with its named competitors (603014.SS vs FME.DE vs BAX vs 300529.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Shandong Weigao Blood Purification Products 603014.SS$3.63B-1%+4%n/a20.4×-1.2%
Fresenius Medical Care FME.DE$11.2B+3%-1%11%9.5×-4.8%
Baxter International BAX$13.5B+39%+5%6%12.7×13.4%
Jafron Biomedical 300529.SZ$2.35B+3%+1%37%24.3×6.1%

How Shandong Weigao Blood Purification Products compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shandong Weigao Blood Purification Products against its 20 peers (data as of 18 Nov 2026)
Measure603014.SSPeer medianRank in peer set
1-month return+17.4%+3.0%3rd highest of 21
6-month return-0.8%+3.2%10th lowest of 21
Distance from 52-week high-29.3%-24.1%10th lowest of 21
Revenue growth (TTM)+4.0%+7.4%9th lowest of 21
Forward P/E20.4×24.4×7th cheapest of 19
Growth the price implies (Req g, 7 yrs)-1.2%12.5%3rd least demanding of 18
Growth delivered (Del g)+8.1%+8.9%9th lowest of 18
Hurdle (Req g minus delivered)-9.3 pp+1.5 pp3rd least demanding of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shandong Weigao Blood Purification Products 603014.SSChina$3.63B-1%+4%n/a20.4×-1.2%+8.1%
Tecan TECN.SWSwitzerland$3.60B+59%-4%1%35.5×45.4%+3.8%
SCHOTT Pharma AG & Co. KGaA 1SXP.DEGermany$3.73B+32%+4%15%23.0×12.7%+11.0%
Sumitomo Bakelite 4203.TJapan$3.50B+7%+15%13%15.9×8.6%+8.9%
Ambu A/S AMBU-B.CODenmark$3.47B+31%+7%13%28.8×10.0%+10.0%
Envista NVSTUnited States$3.81B0%+10%12%14.7×4.8%+7.1%
Andon Health 002432.SZChina$3.86B-24%-30%-26%16.1×-6.6%-7.4%
Axogen AXGNUnited States$3.40B+33%+24%-5%87.3×52.6%+14.9%
Pulse Biosciences PLSEUnited States$3.37B+76%+1,637%-5,821%n/an/an/a
CareDx CDNAUnited States$3.91B+252%+39%1%50.6×n/an/a
Fielmann FIE.DEGermany$3.92B-3%+3%14%17.1×-5.5%+11.3%
Autobio Diagnostics 603658.SSChina$3.36B+16%+3%25%20.3×-0.4%+7.2%
TransMedics TMDXUnited States$3.35B+42%+28%12%43.4×38.4%+88.2%
iRay Technology 688301.SSChina$3.31B-30%+58%24%25.7×n/an/a
Zhende Medical 603301.SSChina$3.26B-10%+8%7%42.5×22.9%-16.1%
Lepu Medical Technology (Beijing) 300003.SZChina$3.20B-13%-1%13%24.4×8.7%-4.2%
iRhythm IRTCUnited States$3.19B-19%+22%5%99.8×46.9%+23.0%
Carl Zeiss Meditec AFX.DEGermany$3.17B+22%0%8%24.4×12.5%+10.8%
Jiangsu Yuyue Medical Equipment & Supply 002223.SZChina$4.18B-3%-1%13%20.0×4.9%+3.4%
Stevanato STVNUnited States$4.19B-13%+12%18%22.5×13.1%+12.1%
MGI Tech 688114.SSChina$3.06B-4%+2%-7%n/a43.7%-0.1%

Questions

Who are Shandong Weigao Blood Purification Products's main competitors?
Named competitors: Fresenius Medical Care (FME.DE), Baxter International (BAX), Jafron Biomedical (300529.SZ). The cockpit's measured peer set (industry) also includes Tecan (TECN.SW), SCHOTT Pharma AG & Co. KGaA (1SXP.DE), Sumitomo Bakelite (4203.T), Ambu A/S (AMBU-B.CO), Envista (NVST), Andon Health (002432.SZ).
Is Shandong Weigao Blood Purification Products expensive compared with its peers?
On forward p/e it trades at 20.4× against a peer median of 24.4×, 7th cheapest of 19 in its peer set. For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -9 pp: the price already allows for a slowdown.
How has Shandong Weigao Blood Purification Products stock performed?
Over six months to 18 Nov 2026 the shares returned -0.8% against +3.2% for the median peer; over one year -25.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.